Pharmacological treatment of cognitive deficits in Alzheimer's disease

Lam, William

doi:10.5694/j.1326-5377.2002.tb04418.x

Topics

To the Editor: The review by Brodaty and colleagues1 on drug treatment of Alzheimer's disease provides a good, concise and balanced overview. However, Pfizer takes issue with some of the referenced safety data.

Pfizer Pty Ltd, West Ryde, NSW.

Correspondence: Bill.Lam@Pfizer.com

1. Brodaty H, Ames D, Boundy KL, et al. Pharmacological treatment of cognitive deficits in Alzheimer's disease [review]. Med J Aust 2001; 175: 324-329.
2. Rogers S, Friedhoff L. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study. Eur Neuropsychopharmacol 1998; 8: 67-75.
3. Australian-approved Product Information for Donepezil. Sydney: Pfizer Pty Limited, 10 December 2001.
4. Winblad B, Engedal K, Soininen H, et al and the Donepezil Nordic Study Group. A 1-year, randomized, placebo-controlled study of donepezii in patients with mild to moderate AD. Neurology 2001; 57: 489-495.

Online responses are no longer available. Please refer to our instructions for authors page for more information.